Capsugel announced that it has completed construction of a new pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its site in Bend, Ore. The completion represents the final phase of a two-year, $25 million investment....
NanoSphere Health Sciences is the first and only patent-pending nanoparticle delivery system for...
During the first 11 months of 2014, the industry saw $15.3 billion in venture capital compared...
“The microchip-based implant is truly at the intersection of digital technology and medicine and...
Pursuant to the agreement, Arrowhead will acquire all shares of BTMI from the BTMI shareholders in exchange for 41.5 million common shares of Arrowhead.
While the pancreatic cancer treatment pipeline contains 447 therapeutics in active development across all phases, compared to 209 currently-marketed products, almost 75 percent of therapies are in Phase I or earlier.
Methamphetamine is a highly addictive drug and its production can be highly flammable.
The antipsychotic medication for treatment of depression, bipolar disorder and schizophrenia totaled $7.2 billion in sales between June 2013 and June 2014.
Greengro was recently featured on Forbes list of "hottest marijuana companies" and continues to gain momentum.
Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin".
Prescription drug sales are forecasted to grow nearly 5% annually over the next five years.
One driver for the company's success is the increased emphasis on strategic partnerships with manufacturers.
Deloitte's report suggests that biopharmaceutical companies could have greater success if they collaborate with other organizations — even competitors — as part of an open innovation approach to research and development.
The plans include the construction of a new 30,000 square foot, state-of-the-art, fully GMP-compliant cleanroom facility.
Walgreens Boots Alliance, Inc. is recalling a line of women's multivitamins because the packaging is not child-resistant.
ITP affects as many as 5 in 100,000 children each year and is characterized by a low platelet count.
Carna Biosciences today announced a worldwide licensing agreement with Janssen Biotech to further develop and commercialize compounds from one of Carna Bioscience’s small molecule protein kinase inhibitor programs.
The new Sipp Industries Hemp unit will have large-volume hemp ingredients available, including toasted hemp seeds, hulled hemp seeds, hemp protein powder, cold-pressed hemp oil, and purely refined hemp oil.
The program focused on a next generation selective glucocorticoid receptor antagonist in development for the treatment of Cushing’s syndrome and certain cancers.
The CDMO unveiled initiatives that include additional staff for daily clinical manufacturing operations, as well as the doubling of capacities for performing visual inspection and in-process control.
"The demand for our characterization services from North and South America has also been strong," said BioPharmaSpec Founder and President Professor Howard R. Morris.
The project will create a new forum for collaborative analysis of Janssen's clinical trial data with data available from the National Institutes of Health (NIH) about schizophrenia.
RecAP is currently in Phase II development for testing the potential treatment of acute kidney injury, with the potential to be developed for hypophosphatasia.
Seattle Genetics has a substantial portfolio of cancer targets and tumor-specific monoclonal antibodies from which programs will be selected for the collaboration.
The novelty covers the method of preparing master cell banks, working cell banks and the final therapeutic product "Stempeucel" based on the novel pooling technology.
Thursday's suspension leaves about 250 people in 46 NIH studies waiting to hear when they will receive other experimental treatments.
Promising trial results for a new drug designed to treat aggressive breast cancer helped Pfizer double its share of that market, according to CEO Ian Read.
The ongoing spat between generic pharmaceutical rivals Teva and Mylan shows no signs of slowing down.
- Page 1